Reported results
- GAAP net income for the third quarter of 2026 was $38 million, or $0.73 per diluted share.
- Adjusted net income for the third quarter of 2026 was $46 million, or $0.89 per diluted share.
- Premium revenue was approximately $10.5 billion for the third quarter of 2026.
- The consolidated MCR for the third quarter of 2026 was 92.9%.
- The G&A ratio for the third quarter of 2026 was 6.4% and the adjusted G&A ratio was 6.3%.
Guidance
- Full year 2026 premium revenue of approximately $42 billion.
- Full year 2026 GAAP earnings of at least $2.38 per diluted share.
- Full year 2026 adjusted earnings of at least $5.25 per diluted share.
Notes
The nine months ended September 30, 2026 includes a $93 million impairment charge resulting from the decision to exit the Medicare Advantage Prescription Drug product for 2027.
Price and volatility reaction
The stock moved +0.8% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -16.7 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 214.9 | 2026-10-21 |
| Close after release | 216.64 | 2026-10-22 |
| Realised move | +0.8% | close to close |
| 30d ATM IV change | -16.7 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-21 (8-K, Item 2.02). Read the original filing on sec.gov.
